Doubles its single-use manufacturing capabilities
Rentschler Biotechnologie, a German contract manufacturing and development organisation (CDMO) for biopharmaceuticals, has put its new 2,000L single-use bioreactor into operation.
The new bioreactor, built and commissioned in only six months, doubles Rentschler’s single-use manufacturing capabilities. It integrates with the existing manufacturing suites by supplementing two 1,000L single-use bioreactors.
Frank Ternes, Chief Business Officer at Rentschler, said: 'The new bioreactor is already very well booked months before its commissioning which proves the high level of confidence customers have in our company.
'With this new addition to our facility we strengthen our position in single-use biomanufacturing further and get closer to our goal to manufacture Phase III clinical and market supplies completely in single-use.'
Rentschler has more than five years’ experience with single-use bioreactors and its manufacturing facility has a flexible space concept and movable equipment. The company says single-use equipment reduces contamination risks and manufacturing costs. It permits a faster product turnaround and a shortened setup time and increases the capacity utilisation.
The company is also experiencing a high demand for stainless steel manufacturing and has already announced an investment of €24m to build a Twin system with two 3,000L stainless steel bioreactors.